Safety Evaluation Study for Patients With Polycythemia Vera

Last updated: July 21, 2023
Sponsor: Perseus Proteomics Inc.
Overall Status: Active - Recruiting

Phase

1

Condition

Leukemia (Pediatric)

Red Blood Cell Disorders

Bone Marrow Disorder

Treatment

PPMX-T003

Clinical Study ID

NCT05074550
PPMX-T003-CT102
  • Ages 20-75
  • All Genders

Study Summary

This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classificationcriteria
  • PV patients being only treated with phlebotomy and the interval is 4-9 weeks

Exclusion

Exclusion Criteria:

  • Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib (aspirin is excluded)

Study Design

Total Participants: 6
Treatment Group(s): 1
Primary Treatment: PPMX-T003
Phase: 1
Study Start date:
August 24, 2022
Estimated Completion Date:
March 31, 2024

Connect with a study center

  • Kansai Medical University Hospital

    Hirakata, Osaka 573-1191
    Japan

    Active - Recruiting

  • Shimane University Hospital

    Izumo, Shimane 693-8501
    Japan

    Active - Recruiting

  • Osaka City University Hospital

    Osaka, 545-8586
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.